{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:37:15Z","timestamp":1765546635869,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","award":["ACoP6"],"award-info":[{"award-number":["ACoP6"]}],"id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010032","name":"Health and Family Planning Commission of Sichuan Province","doi-asserted-by":"publisher","award":["2016ZB0301-01"],"award-info":[{"award-number":["2016ZB0301-01"]}],"id":[{"id":"10.13039\/501100010032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010120","name":"Huashan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010120","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573505"],"award-info":[{"award-number":["81573505"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.yebeh.2020.107265","type":"journal-article","created":{"date-parts":[[2020,7,5]],"date-time":"2020-07-05T17:15:26Z","timestamp":1593969326000},"page":"107265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Remedial dosing recommendations for delayed or missed doses of valproic acid in patients with epilepsy based on Monte Carlo simulations"],"prefix":"10.1016","volume":"111","author":[{"given":"Chen-yu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7999-7162","authenticated-orcid":false,"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-jie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Er-qian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-xing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.yebeh.2020.107265_bb0005","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.yebeh.2020.107265_bb0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.yebeh.2008.12.006","article-title":"Association of antiepileptic drug nonadherence with risk of seizures in adults with epilepsy","volume":"14","author":"Manjunath","year":"2009","journal-title":"Epilepsy Behav"},{"issue":"20","key":"10.1016\/j.yebeh.2020.107265_bb0015","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","article-title":"Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study","volume":"71","author":"Faught","year":"2008","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.yebeh.2020.107265_bb0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1525-5050(02)00037-9","article-title":"The relationship between poor medication compliance and seizures","volume":"3","author":"Cramer","year":"2002","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2020.107265_bb0025","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1528-1167.2007.01414.x","article-title":"Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population","volume":"49","author":"Davis","year":"2008","journal-title":"Epilepsia"},{"year":"2019","series-title":"Depakene\u00ae. [package insert]","key":"10.1016\/j.yebeh.2020.107265_bb0030"},{"issue":"2","key":"10.1016\/j.yebeh.2020.107265_bb0035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev"},{"issue":"1","key":"10.1016\/j.yebeh.2020.107265_bb0040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00023210-200822010-00003","article-title":"Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy","volume":"22","author":"Landmark","year":"2008","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.yebeh.2020.107265_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11910-017-0758-6","article-title":"The new classification of seizures by the International League Against Epilepsy 2017","volume":"17","author":"Fisher","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"11","key":"10.1016\/j.yebeh.2020.107265_bb0050","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/aps.2012.135","article-title":"The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharmacol Sin"},{"issue":"9","key":"10.1016\/j.yebeh.2020.107265_bb0055","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/bdd.473","article-title":"The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations","volume":"26","author":"Ahmad","year":"2005","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.yebeh.2020.107265_bb0060","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003088-200140010-00002","article-title":"A brief introduction to Monte Carlo simulation","volume":"40","author":"Bonate","year":"2001","journal-title":"Clin Pharmacokinet"},{"year":"2013","series-title":"Handbook of Monte Carlo methods","author":"Kroese","key":"10.1016\/j.yebeh.2020.107265_bb0065"},{"issue":"8","key":"10.1016\/j.yebeh.2020.107265_bb0070","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF03261928","article-title":"Fundamentals of population pharmacokinetic Modelling","volume":"51","author":"Kiang","year":"2012","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.yebeh.2020.107265_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13318-019-00598-0","article-title":"How to handle delayed or missed doses: a population pharmacokinetic perspective","volume":"45","author":"Gu","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"10.1016\/j.yebeh.2020.107265_bb0080","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.yebeh.2020.107265_bb0085","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1017\/PHN20062005","article-title":"Comparison of the World Health Organization (WHO) child growth standards and the National Center for Health Statistics\/WHO international growth reference: implications for child health programmes","volume":"9","author":"de Onis","year":"2006","journal-title":"Public Health Nutr"},{"key":"10.1016\/j.yebeh.2020.107265_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"issue":"3","key":"10.1016\/j.yebeh.2020.107265_bb0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00003088-200038030-00001","article-title":"Is there a role for therapeutic drug monitoring of new anticonvulsants?","volume":"38","author":"Perucca","year":"2000","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.yebeh.2020.107265_bb0100","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2014best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2020.107265_bb0105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","article-title":"Valproate population pharmacokinetics in children","volume":"24","author":"Serrano","year":"1999","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.yebeh.2020.107265_bb0110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","article-title":"Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data","volume":"20","author":"Serrano","year":"1999","journal-title":"Biopharm Drug Dispos"},{"issue":"9","key":"10.1016\/j.yebeh.2020.107265_bb0115","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/bdd.636","article-title":"Population pharmacokinetics of valproate in Mexican children with epilepsy","volume":"29","author":"Correa","year":"2008","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"10.1016\/j.yebeh.2020.107265_bb0120","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejps.2009.09.017","article-title":"The influence of drug-drug interaction and patients' characteristics on valproic acid's clearance in adults with epilepsy using nonlinear mixed effects modeling","volume":"38","author":"Vucicevic","year":"2009","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.yebeh.2020.107265_bb0125","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1177\/0091270011428138","article-title":"Population pharmacokinetics of valproic acid in pediatric patients with epilepsy: considerations for dosing spinal muscular atrophy patients","volume":"52","author":"Williams","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2020.107265_bb0130","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FTD.0000000000000100","article-title":"Population pharmacokinetics of valproic acid in adult Chinese epileptic patients and its application in an individualized dosage regimen","volume":"37","author":"Lin","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"2\u20133","key":"10.1016\/j.yebeh.2020.107265_bb0135","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eplepsyres.2010.08.002","article-title":"Patterns of prescription of antiepileptic drugs in patients with refractory epilepsy at tertiary referral centres in Italy","volume":"91","author":"Malerba","year":"2010","journal-title":"Epilepsy Res"},{"year":"2011","series-title":"Pharmacokinetic-pharmacodynamic modeling and simulation","author":"Bonate","key":"10.1016\/j.yebeh.2020.107265_bb0140"},{"issue":"5","key":"10.1016\/j.yebeh.2020.107265_bb0145","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/FTD.0b013e31811f3296","article-title":"Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents","volume":"29","author":"Birnbaum","year":"2007","journal-title":"Ther Drug Monit"},{"issue":"10","key":"10.1016\/j.yebeh.2020.107265_bb0150","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1111\/j.1745-7254.2007.00704.x","article-title":"Population pharmacokinetics of valproate in Chinese children with epilepsy","volume":"28","author":"Jiang","year":"2007","journal-title":"Acta Pharmacol Sin"},{"issue":"12","key":"10.1016\/j.yebeh.2020.107265_bb0155","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":"Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.yebeh.2020.107265_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0111066","article-title":"Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of \u03b3-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis","volume":"9","author":"Ogusu","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.yebeh.2020.107265_bb0165","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40262-014-0212-8","article-title":"A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation","volume":"54","author":"Ding","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.yebeh.2020.107265_bb0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2710.2006.00739.x","article-title":"Effect of delayed and\/or missed enteric-coated divalproex doses on valproic acid concentrations: simulation and dose replacement recommendations for the clinician","volume":"31","author":"Dutta","year":"2006","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.yebeh.2020.107265_bb0175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1345\/aph.1G617","article-title":"Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets\u2014clinical implications","volume":"40","author":"Dutta","year":"2006","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2020.107265_bb0180","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/ajhp\/61.21.2284","article-title":"Predicted serum valproic acid concentrations in patients missing and replacing a dose of extended-release divalproex sodium","volume":"61","author":"Reed","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.yebeh.2020.107265_bb0185","doi-asserted-by":"crossref","first-page":"904","DOI":"10.2146\/ajhp050147","article-title":"Predicted plasma valproic acid concentrations in patients missing and replacing a full daily dose of extended-release divalproex sodium","volume":"63","author":"Dutta","year":"2006","journal-title":"Am J Health Syst Pharm"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020304443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505020304443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:37:20Z","timestamp":1761503840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505020304443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":37,"alternative-id":["S1525505020304443"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107265","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remedial dosing recommendations for delayed or missed doses of valproic acid in patients with epilepsy based on Monte Carlo simulations","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.107265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107265"}}